Miragen Therapeutics Inc (OQ:MGEN)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 6200 Lookout Rd
BOULDER CO 80301-3319
Tel: N/A
Website: www.miragen.com
IR: See website
Key People
Jeffrey S. Hatfield
Independent Chairman of the Board
Lee M. Rauch
President, Chief Executive Officer, Director
Jason A. Leverone
Principal Financial Officer, Principal Accounting Officer, Treasurer, Secretary
Diana Escolar
Chief Medical Officer
Business Overview
Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155 (miR-155), which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is involved in discovering and developing a pipeline of pre-clinical product candidates. Its pre-clinical product candidates include MRG-107 and MRG-110.
Financial Overview
For the six months ended 30 June 2020, Miragen Therapeutics Inc revenues decreased 65% to $996K. Net loss decreased 29% to $14.5M. Revenues reflect Collaboration revenue decrease of 76% to $681K. Lower net loss reflects Research and Development - Balancing val decrease of 44% to $9.2M (expense), Stock-based Compensation in R&D decrease of 56% to $357K (expense), Selling and marketing - Balancing value decrease of 9% to $4.5M (expense).
Employees: 45 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $23.96M as of Jun 30, 2020
Annual revenue (TTM): $2.57M as of Jun 30, 2020
EBITDA (TTM): -$34.73M as of Jun 30, 2020
Net annual income (TTM): -$35.83M as of Jun 30, 2020
Free cash flow (TTM): -$32.34M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 56,610,154 as of Jul 29, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.